	US 12,103,978 B2
	Methods and materials for treating cancer
Chaohong Hu, Shanghai (CN); Hu Li, Shanghai (CN); Wenchao Liu, Shanghai (CN); and Zhenyu Dai, Shanghai (CN)
Assigned to SHANGHAI MIRACOGEN INC., Shanghai (CN)
Appl. No. 16/763,335
Filed by SHANGHAI MIRACOGEN INC., Shanghai (CN)
PCT Filed Jun. 15, 2018, PCT No. PCT/CN2018/091444 § 371(c)(1), (2) Date May 12, 2020, PCT Pub. No. WO2019/237322, PCT Pub. Date Dec. 19, 2019.
Prior Publication US 2021/0087292 A1, Mar. 25, 2021
Int. Cl. C07K 16/32 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/32 (2013.01) [A61K 39/39541 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. An antibody-drug conjugate comprising:

an anti-HER2 antibody having greater than about 90% fucosylation,

at least one molecule of an anti-cancer drug, and

a linker connecting the anti-HER2 antibody and the at least on molecule of said anti-cancer drug,

wherein said anti-HER2 antibody is a humanized IgG antibody that comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:4 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:8 or 9,

wherein the anti-cancer drug is monomethyl auristatin E, and

wherein the linker comprises a valine citruline dipeptide linker.